Literature DB >> 833261

Cushing's disease: growth hormone response to hypoglycemia after correction of hypercortisolism.

J B Tyrrell, J Wiener-Kronish, M Lorenzi, R M Brooks, P H Forsham.   

Abstract

Growth hormone responses to insulin-induced hypoglycemia were studied in 17 patients with inactive Cushing's disease. A normal GH rise was found in 9 of 9 patients without evidence of progressive pituitary tumor after bilateral adrenalectomy and 3 of 4 patients after correction of hypercortisolism by transsphenoidal removal of pituitary microadenomas. In contrast, 3 of 4 patients with Nelson's syndrome had impaired GH responsiveness to hypoglycemia. These results show that GH responsiveness is normal in the majority of patients with inactive Cushing's disease and do not support the concept of a primary hypothalamic or central nervous system abnormality of GH regulation in Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 833261     DOI: 10.1210/jcem-44-1-218

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Pituitary function before and after transsphenoidal adenomectomy in patients with Cushing's disease.

Authors:  B Ambrosi; M Giovanelli; S M Gaini; D Bochicchio; E Riva; G Tomei; M Zavanone; G Faglia
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

2.  Cushing's disease presenting with growth failure: clinical remission during cyproheptadine therapy.

Authors:  D B Grant; S M Atherden
Journal:  Arch Dis Child       Date:  1979-06       Impact factor: 3.791

3.  ACTH 1-17 stimulates GH pituitary secretion in humans.

Authors:  G Valenti; A Banchini; L Denti; R Polotti; G P Ceda
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

4.  Anterior pituitary function after adrenalectomy in patients with Cushing's syndrome.

Authors:  M Marazuela; C Cuerda; T Lucas; A Vicente; C Blanco; J Estrada
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.